Redx Pharma マネジメント

マネジメント基準チェック /34

Redx Pharmaの CEO はLisa Mary Ansonで、 Jun2018年に任命され、の在任期間は 5.92年です。の年間総報酬は£ 608.13Kで、 94.9%給与と5.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.19%を直接所有しており、その価値は£ 112.75K 。経営陣と取締役会の平均在任期間はそれぞれ3年と3年です。

主要情報

Lisa Mary Anson

最高経営責任者

UK£608.1k

報酬総額

CEO給与比率	94.9%
CEO在任期間	5.9yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Jul 09

CEO報酬分析

Redx Pharma の収益と比較して、Lisa Mary Anson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	UK£608k	UK£577k	-UK£33m
Jun 30 2023	n/a	n/a	-UK£31m
Mar 31 2023	n/a	n/a	-UK£29m
Dec 31 2022	n/a	n/a	-UK£24m
Sep 30 2022	UK£637k	UK£606k	-UK£18m
Jun 30 2022	n/a	n/a	-UK£18m
Mar 31 2022	n/a	n/a	-UK£19m
Dec 31 2021	n/a	n/a	-UK£20m
Sep 30 2021	UK£2m	UK£615k	-UK£22m
Jun 30 2021	n/a	n/a	-UK£20m
Mar 31 2021	n/a	n/a	-UK£18m
Dec 31 2020	n/a	n/a	-UK£14m
Sep 30 2020	UK£619k	UK£481k	-UK£9m
Jun 30 2020	n/a	n/a	-UK£8m
Mar 31 2020	n/a	n/a	-UK£6m
Dec 31 2019	n/a	n/a	-UK£5m
Sep 30 2019	UK£439k	UK£390k	-UK£4m
Jun 30 2019	n/a	n/a	-UK£5m
Mar 31 2019	n/a	n/a	-UK£7m
Dec 31 2018	n/a	n/a	-UK£8m
Sep 30 2018	UK£372k	UK£100k	-UK£9m

報酬と市場: Lisa Maryの総報酬 ($USD 759.28K ) は、 UK市場 ($USD 354.57K ) の同規模の企業の平均を上回っています。

報酬と収益: Lisa Maryの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Lisa Mary Anson (55 yo)

5.9yrs

在職期間

UK£608,127

報酬

Mrs. Lisa Mary Whewell Anson serves as the Chief Executive Officer and Executive Director at Redx Pharma PLC since June 1, 2018. She has been President of AstraZeneca UK since 2012 and brings significant l...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lisa Mary Anson	CEO & Executive Director	5.9yrs	UK£608.13k	0.19% £ 112.8k
Peter Collum	Chief Financial Officer	3yrs	データなし	データなし
James Mead	Chief Operating Officer	3yrs	UK£210.91k	データなし
Richard Armer	Chief Scientific Officer	10.3yrs	データなし	データなし
Karl Hard	Head of Investor Relations	no data	データなし	データなし
Claire Solk	General Counsel & Company Secretary	2.3yrs	データなし	データなし
Caitlin Pearson	Head of Communications	2.1yrs	データなし	データなし
Cliff Jones	Senior Vice President of Chemistry	8.3yrs	データなし	データなし
Caroline Phillips	Senior Vice President of Biology	no data	データなし	データなし
Craig Tilston	Head of Development Operations	no data	データなし	データなし
Helen McKeever	Head of Nonclinical Development	3.3yrs	データなし	データなし
Helen Timmis	Interim Chief Medical Officer	less than a year	データなし	データなし

3.0yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: REDXの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Lisa Mary Anson	CEO & Executive Director	5.9yrs	UK£608.13k	0.19% £ 112.8k
Peter Presland	Independent Non-Executive Director	6.5yrs	UK£48.75k	0.038% £ 21.9k
Joseph Anderson	Non-Executive Director	less than a year	データなし	データなし
Bernhard Kirschbaum	Independent Non-Executive Director	8.3yrs	UK£49.00k	データなし
Jane Griffiths	Independent Non-Executive Chair	2.4yrs	UK£85.00k	0.022% £ 12.7k
Robert Andrew Scott	Independent Non-Executive Director	2.3yrs	UK£41.50k	データなし
Natalie Berner	Shareholder Representative Non-Executive Director	3yrs	データなし	データなし

3.0yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: REDXの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Redx Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Redx Pharma Plc Announces Directorate Changes

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

High number of new directors

Recent updates

Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress

Redx to Present Zamaporvint Phase2 Data At Esmo Gi

Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress

Redx Pharma Provides Update on AIM Delisting

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.062 loss

Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

New minor risk - Share price stability

New minor risk - Market cap size

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million.

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation

New minor risk - Market cap size

Redx Pharma Plc Announces Directorate Changes

Is Redx Pharma (LON:REDX) Using Too Much Debt?

Price target decreased by 9.9% to UK£1.32

First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022)

Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park

Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme

Consensus revenue estimates increase by 15%, EPS downgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022

High number of new directors

Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting

Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 31%

Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June

First half 2022 earnings released

Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million.

Price target increased to UK£1.70

High number of new directors

Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data

Redx Pharma plc Announces Nomination of Clinical Development Candidate

Redx Pharma Plc Announces Committee Changes

Redx Pharma Plc, Annual General Meeting, Mar 08, 2022

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020)

Non-Executive Chairman Iain Ross has left the company

Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor

Redx Pharma Announce Mead Will Step Down from the Board

Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated

Chief Medical Officer has left the company

New 90-day high: UK£0.68

Redx Pharma Plc, Annual General Meeting, Mar 02, 2021

Earnings beat expectations, revenue disappoints

Redx Pharma Plc to Report Fiscal Year 2020 Results on Jan 27, 2021

New 90-day low: UK£0.54

Redx Pharma plc Announces the Appointment of Jane Robertson as Chief Medical Officer, Effective 1 March 2021

New 90-day high: UK£0.68

New 90-day high - UK£0.60

Redmile Group, LLC completed the acquisition of remaining 54.5% stake in Redx Pharma Plc (AIM:REDX).

Redx Pharma Plc announced that it expects to receive £23.63877 million in funding from Sofinnova Partners SAS, Redmile Group, LLC

マネジメント基準チェック /34